Evidence map›Paper›PMID 31608067›Full record

ReviewFrontiers in immunology2019

Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.

Chakradhar Yakkala, Cheryl Lai-Lai Chiang, Lana Kandalaft, Alban Denys, Rafael Duran

Registry-linked trialAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05622825 (Evaluation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05622825 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Evaluation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers

TypeinterventionalSponsorNational Taiwan University HospitalRan2023 to 2024Enrolled15ConditionsAdvanced Liver CancersArmsDC-CIK
3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Tissue Ablation: Applications and Perspectives.Advanced materials (Deerfield Beach, Fla.) · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chakradhar YakkalaDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.
Cheryl Lai-Lai ChiangVaccine Development Laboratory, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland.
Lana KandalaftVaccine Development Laboratory, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland.
Alban DenysDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.
Rafael DuranDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of solid tumors by ablation techniques has gained momentum in the recent years due to their technical simplicity and reduced morbidity as juxtaposed to surgery. Cryoablation is one of such techniques, known for its uniqueness to destroy the tumors by freezing to lethal temperatures. Freezing the tumor locally and allowing it to remain

Indexed as

Antigens, NeoplasmClinical Trials as TopicCombined Modality TherapyCryosurgeryHumansImmune SystemImmunotherapyNeoplasmsTreatment OutcomeAntigens, Neoplasmablationcryofreezingimmunotherapytreatmenttumors

Identifiers

PMID31608067
PMCPMC6769045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.